Protagonist Therapeutics, Inc. $PTGX Shares Purchased by American Century Companies Inc.

American Century Companies Inc. boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 18.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 813,995 shares of the company’s stock after purchasing an additional 128,171 shares during the quarter. American Century Companies Inc. owned approximately 1.31% of Protagonist Therapeutics worth $44,990,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. FNY Investment Advisers LLC acquired a new position in shares of Protagonist Therapeutics during the 2nd quarter worth $27,000. Bessemer Group Inc. increased its holdings in Protagonist Therapeutics by 171.0% during the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after acquiring an additional 318 shares in the last quarter. CWM LLC increased its holdings in Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after acquiring an additional 407 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Protagonist Therapeutics by 141.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company’s stock worth $59,000 after acquiring an additional 710 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new position in Protagonist Therapeutics during the first quarter worth about $68,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $89.98 on Friday. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.70 and a fifty-two week high of $93.25. The company has a market capitalization of $5.63 billion, a PE ratio of 145.12 and a beta of 2.22. The stock has a fifty day moving average of $76.65 and a two-hundred day moving average of $61.81.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The business had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. As a group, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the completion of the sale, the director owned 5,130 shares in the company, valued at $418,710.60. The trade was a 70.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. BTIG Research reiterated a “buy” rating and issued a $82.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. Wedbush upped their target price on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research note on Tuesday, October 28th. Barclays increased their target price on Protagonist Therapeutics from $72.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Leerink Partnrs raised Protagonist Therapeutics to a “strong-buy” rating in a report on Friday, September 12th. Finally, JMP Securities upped their price objective on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $82.23.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.